RedHill expands manufacturing capacity for opaganib with Cosmo
pharmafile | January 29, 2021 | News story | Medical Communications | RedHill Biopharma
RedHill Biopharma has announced a manufacturing agreement with Cosmo Pharmaceuticals to further expand manufacturing capacity for opaganib (Yeliva), to address prospective demand subsequent to potential global emergency use authorisations.
The global Phase II/III study of opaganib in severe COVID-19 pneumonia is ongoing, with patients enrolled in over 30 sites in multiple countries. An interim independent Data and Safety Monitoring Board (DSMB) futility analysis will be conducted in the coming days, evaluating data from the first 135 subjects that have reached the primary endpoint. The study has previously undergone two unblinded independent DSMB safety data reviews, with unanimous recommendations to continue the study.
Early data from a non-powered US Phase II study of 40 hospitalised patients recently showed that opaganib was safe, and demonstrated greater improvement in reducing oxygen requirement by end of treatment on day 14 across key primary and secondary efficacy outcomes. The findings correlate with clinical improvement as defined by the WHO ordinal scale.
Reza Fathi, Senior Vice President of R&D at RedHill, said: “The growing concerns over viral mutations and the spread of new potent and evasive viral strains have increased the dire need for new COVID-19 therapeutics.
“We are very pleased to expand the manufacturing capacity of opaganib with a partner of Cosmo’s quality. Opaganib is designed to act broadly against different viral strains irrespective of mutations in the spike protein.
“Opaganib is a Phase II/III-stage novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated antiviral, anti-inflammatory, and anti-thrombotic activity. By targeting SK2, a human cell component involved in viral replication irrespective of mutations in the viral spike protein, opaganib potentially addresses the emergence of new strains.”
Davide Malavasi, Cosmo’s Head of Manufacturing, added: “We are delighted to further strengthen our partnership with RedHill on expanded opaganib manufacturing, and to play a part in trying to help alleviate the suffering the coronavirus pandemic is causing across the world, should opaganib be approved for use.”
Darcy Jimenez
Related Content
RedHill Biopharma to expand COVID-19 opaganib trial to US
RedHill Biopharma has announced its plans to expand the company’s global Phase II/III study of …
RedHill enters manufacturing deal with Cosmo for two key products
RedHill Biopharma has announced agreements with Cosmo Pharmaceuticals to manufacture two of RedHill’s key products. …
FDA approves RedHill Biopharma’s Talicia to combat Helicobacter pylori infection
RedHill Biopharma is celebrating after the FDA chose to award marketing authorisation to Talicia (omeprazole …
